On June 15, 2026 the plaintiffs’ leadership counsel in the federal Depo-Provera litigation announced a settlement of a majority of the claims in the MDL and in New York state court. A Master Settlement Agreement was signed on July 21. The parties estimate that roughly 80% of the plaintiffs in the MDL will be eligible to take part, out of 6,289 member actions on the docket as of late July. On August 5 the court appointed BrownGreer PLC as settlement administrator. Registration is expected to be completed in November 2026, with payments beginning to roll out by the first quarter of 2027. One feature of the deal is worth understanding before anything else: it is a private agreement, and no court will rule on whether its terms are fair. That is not a defect. It is a consequence of the fact that an MDL is not a class action.
What was announced, and when
The chronology is short and almost entirely procedural. On June 15, 2026 leadership counsel told the court that a settlement had been reached covering a majority of the claims in the MDL and in the parallel New York state court proceeding. The court responded by vacating the scheduling order for the pilot cases — the plaintiffs in those cases were themselves eligible to participate — and canceling the trial that had been set for December 7, 2026.
A Master Settlement Agreement was signed by the parties on July 21, 2026. At the case management conference on July 27, counsel for both sides gave the court a brief overview of it, and the court recorded three things about its scope: eligibility is defined inside the agreement, the agreement is governed by a confidentiality agreement that the court will enforce, and eligibility will not be affected by any future ruling on the legal questions still outstanding in the MDL.
On August 5, 2026 the court appointed BrownGreer PLC — already serving as the litigation’s data administrator — as settlement administrator, with responsibility for eligibility determinations, review of submitted records, fraud protection measures and coordination of payment.
Why no court will pass on the terms
In a class action, a settlement binds people who never filed anything, so a judge has to find it fair, reasonable and adequate before it takes effect. That is the fairness hearing people have read about in other mass litigation. It does not happen here, because this litigation is not a class action. The court’s own order says so plainly: the settlement is not subject to a fairness determination because this MDL is not a class action.
What an MDL does is different. Individual federal lawsuits that share common questions are transferred to one judge for pretrial handling, and each case remains the individual’s own case. Nobody is swept in by definition, and nobody is settled without agreeing. The trade-off is that the terms are negotiated privately between the parties and their counsel rather than reviewed in open court.
A private settlement is not a worse settlement. It is a settlement whose terms nobody but the parties has evaluated.
Having been told what the agreement says, the judge did volunteer an opinion — that the settlement offers an excellent outcome to thousands of eligible litigants, who now have the opportunity to resolve their claims without protracted litigation or undue expense. That is a judge’s assessment, offered after being briefed on confidential terms. It is not a legal finding, and it carries no appeal.
What the settlement does not decide
- It contains no admission of fault or liability. The defendants have disputed the allegations throughout and maintain the medication is safe and effective.
- It does not resolve whether Depo-Provera can cause meningioma. The general causation question and the parties’ Rule 702 motions were fully briefed by June 5, 2026 and are set for a hearing on September 18, 2026.
- It does not resolve the preemption question, which was argued earlier and is awaiting decision.
- Those rulings, when they come, will apply to cases that are ineligible for the settlement or that opt out — not to plaintiffs who are eligible and elect to participate.
- It does not end the litigation. Cases have continued to be filed since June, though at a greatly reduced rate, and state court proceedings continue in New York, Delaware, California, Minnesota and several other states.
The timetable, as the court has it
Settlement registration should be completed in November 2026. The claims process then begins to run, with payments beginning to roll out by the first quarter of 2027. To keep filing fees from becoming an obstacle for people whose only purpose in filing is to participate, the court agreed to establish a no-fee administrative docket: a case sits there without a filing fee, and moves to the active docket — and owes the fee — only if the plaintiff is ultimately found ineligible and decides to litigate.
Two caveats belong on any timetable of this kind. Dates in a settlement program slip, and eligibility is decided by the agreement’s own terms rather than by how strong a case looks on the medicine. Anyone with a pending claim should be asking their own counsel which side of the eligibility line they fall on, because the answer determines nearly everything that happens next.
This article is general information about how these cases work. It is not legal advice, it does not create an attorney-client relationship, and no two claims are alike. If something here sounds like your situation, the useful next step is a conversation about the facts.
